You are here

Article Text

Article menu
Download PDFPDF
Letter
Effect size in CANTOS trial
  1. Nanda Gamad,
  2. Nusrat Shafiq,
  3. Samir Malhotra
  1. Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
  1. Correspondence to Dr Samir Malhotra, Post Graduate Institute Medical Education and Research, Chandigarh 160012, India; smal.pgi{at}gmail.com

https://doi.org/10.1136/ebmed-2017-110881

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The primary endpoint in Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial published by Ridker et al 1 was non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. The authors concluded that canakinumab 150 mg reduced primary event rates compared with placebo (3.86 vs 4.11 per 100 person-years) with HR 0.85 (95%CI 0.74 to 0.98; P=0.021). Sample …

    View Full Text

    Footnotes

    • Contributors NG wrote the first draft of the letter. All three authors took the final decision and contributed in the final version.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.